#1 Clinical Trials Search in Europe

Study on the Effects of Atezolizumab, Trastuzumab, and Pertuzumab in Patients with Early-Stage Triple-Negative or HER2+ Breast Cancer

2 1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a new treatment approach for patients with early-stage breast cancer, specifically those with triple-negative or HER2-positive types. The treatment involves using a combination of medications, including Atezolizumab (also known by its code name RO5541267), Trastuzumab, Pertuzumab, and Bevacizumab. These medications are given as solutions for infusion, which means they are administered directly into the bloodstream through a vein.

The purpose of the study is to explore whether a short course of immunotherapy, which is a type of treatment that helps the immune system fight cancer, can increase the activity of certain immune cells in the body. The study will compare the effects of these medications on the immune system before and after treatment. Participants will receive the treatment before their standard cancer therapy, and the study will involve taking samples from the tumor to analyze changes in immune cell activity.

Throughout the study, participants will receive the medications intravenously, and their health will be monitored closely. The study aims to understand how these medications affect the immune system and whether they can improve the body’s ability to fight cancer. The trial will also look at any side effects that may occur during the treatment period and up to four weeks after surgery. This research could provide valuable insights into new ways to treat early-stage breast cancer.

1 joining the study

Upon joining the study, the patient will begin with a series of initial assessments to confirm eligibility. This includes a review of medical history and a physical examination.

The patient will provide informed consent, acknowledging understanding of the study’s procedures and requirements.

2 initial treatment phase

The patient will receive a combination of medications administered through an intravenous infusion. These medications include atezolizumab, pertuzumab, trastuzumab, and bevacizumab.

The specific dosage and frequency of each medication will be determined by the study protocol and the patient’s specific condition.

3 monitoring and assessments

Throughout the treatment phase, the patient will undergo regular monitoring to assess the response to the medications. This includes blood tests and imaging studies.

Biopsies will be performed to evaluate changes in the tumor and immune cell activity.

4 surgery preparation

Following the initial treatment phase, the patient will be prepared for surgery. This involves additional assessments to ensure readiness for the procedure.

The timing of the surgery will be based on the patient’s response to the treatment and the study’s schedule.

5 surgery

The patient will undergo surgery to remove the tumor. The surgical procedure will be performed according to standard medical practices.

Post-surgery, the patient will be monitored for recovery and any potential complications.

6 post-surgery follow-up

After surgery, the patient will continue to be monitored for any changes in health status. This includes regular follow-up visits and assessments.

The study will evaluate the long-term effects of the treatment and the patient’s overall recovery.

Who Can Join the Study?

  • The patient must understand, sign, and date a written consent form before any study-specific procedures are done. They should be willing to attend study visits and follow procedures as outlined in the study plan.
  • Women who can have children must agree to use a very effective birth control method, along with a barrier method like a condom, or choose not to have sexual activity during the study and for a certain period after stopping treatment. This is to prevent pregnancy during the study.
  • Men who are sexually active must agree to use a condom during the study and for a certain period after stopping treatment. It is also recommended that their female partners use a highly effective birth control method during this time.
  • The patient must be part of a social security system or have similar benefits.
  • Both female and male patients must be 18 years or older.
  • The patient should have a good general health status, which is measured by a scale called ECOG performance status, with a score of 0-1 indicating they are fully active or have some symptoms but do not need to stay in bed.
  • The patient must have breast cancer confirmed by a tissue sample, with no signs that the cancer has spread to other parts of the body.
  • The patient should be a candidate for surgery or need standard pre-surgery treatment, with treatment starting after the pre-surgery immunotherapy and biopsies done before starting the treatment.
  • The tumor must be at least 11 mm in size as measured by an ultrasound of the breast.
  • The cancer type must be assessed locally according to specific guidelines: for the triple-negative breast cancer group, certain hormone levels should be low, and for the HER2-positive group, there should be an overexpression of HER2.
  • The patient must have adequate blood and organ function, which includes specific levels of blood cells, proteins, and liver and kidney function tests.
  • Women who can have children must have a negative pregnancy test before starting the study treatment and agree to use effective birth control or abstain from sex during the study and for a certain period after the last dose of treatment.

Who Cannot Join the Study?

  • Patients with a different type of breast cancer than the one specified in the study.
  • Patients with breast cancer that has spread to other parts of the body (metastatic).
  • Patients who have already received treatment for their breast cancer.
  • Patients who are not within the specified age range for the study.
  • Patients who are not able to provide informed consent.
  • Patients with other serious health conditions that might interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who are participating in another clinical trial.
  • Patients with a known allergy to the study drugs.
  • Patients who have had a recent major surgery.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Institut Gustave Roussy Villejuif France
Oncopole Claudius Regaud Toulouse France
Centre Jean Perrin Clermont Ferrand France

Other Sites

Site Name City Country Status
Institut De Cancerologie Strasbourg Europe STRASBOURG, Alsace France
Centre Francois Baclesse Caen France
Crwqnz Hkxqbwlntjt Ee Ucswuzhigrhfs Do Lnvaktp Limoges France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not recruiting
07.03.2022

Trial locations

Investigated drugs:

Atezolizumab is an immunotherapy medication used in this trial to treat early-stage breast cancer. It works by helping the immune system recognize and attack cancer cells more effectively. In this study, it is used to see if it can increase the activity of certain immune cells in the tumor.

Trastuzumab is a targeted therapy used for treating HER2-positive breast cancer. It works by attaching to the HER2 protein on cancer cells, which can help slow or stop the growth of the tumor. In this trial, it is combined with other treatments to evaluate its effectiveness in increasing immune cell activity.

Pertuzumab is another targeted therapy used alongside trastuzumab for HER2-positive breast cancer. It also targets the HER2 protein but works in a slightly different way to help prevent cancer cells from growing. The trial aims to assess its role in enhancing the immune response when used with other therapies.

Investigated diseases:

Triple-Negative Breast Cancer – This is a type of breast cancer that lacks three common receptors known to fuel most breast cancer growth: estrogen, progesterone, and HER2. It is considered more aggressive and has fewer treatment options compared to other breast cancer types. The cancer cells do not respond to hormonal therapy or medicines that target HER2 receptors. It often occurs in younger women and is more likely to spread and recur. The progression can be rapid, and it requires different treatment strategies than other breast cancer types.

HER2-Positive Breast Cancer – This form of breast cancer is characterized by the overexpression of the HER2 protein, which promotes the growth of cancer cells. It tends to grow and spread more quickly than other types of breast cancer. HER2-positive breast cancer can be more aggressive, but it often responds well to targeted therapies that specifically attack the HER2 protein. The disease can affect women of any age, but it is more common in younger women. The progression of the disease can vary, but targeted treatments have improved outcomes significantly.

Trial ID:
2024-512826-26-00
Protocol code:
2020-004696-41
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study on Early Detection of Triple-Negative Breast Cancer Relapse Using 68Ga-FAPI-46 for Patients at High Risk

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

    Recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Hungary +5